Tirzepatide May Enhance Biologic Therapy Outcomes in Psoriatic Arthritis Patients With Obesity

New observational research suggests that addressing obesity alongside inflammatory joint disease could improve treatment outcomes for people with psoriatic arthritis (PsA). As reported on MedIndia, a recent propensity score-matched analysis…

Continue Reading Tirzepatide May Enhance Biologic Therapy Outcomes in Psoriatic Arthritis Patients With Obesity

Impending PPAR-Targeted Therapies Expand Treatment Possibilities for Primary Biliary Cholangitis

As reported on News Medical, researchers are highlighting a new class of therapies that could improve outcomes for people living with primary biliary cholangitis (PBC), a chronic autoimmune liver disease…

Continue Reading Impending PPAR-Targeted Therapies Expand Treatment Possibilities for Primary Biliary Cholangitis

LEVI-04 Shows Promise as a Novel Non-Opioid Therapy for Knee Osteoarthritis in Phase 2 Trial

A recent study shared by The Lancet shows that a first-in-class investigational therapy targeting neurotrophin-3 (NT-3) significantly reduced pain and improved function in patients with knee osteoarthritis (OA), according to…

Continue Reading LEVI-04 Shows Promise as a Novel Non-Opioid Therapy for Knee Osteoarthritis in Phase 2 Trial

Treating Inflammation vs. Bacteria

According to recent reports, assistant pediatric professor at the Boston Children’s Hospital, Prof. Meenakshi Rao, noted that infections associated with Clostridioides difficile (C. Diff.) are difficult to eradicate. Nonetheless, once the infection is under…

Continue Reading Treating Inflammation vs. Bacteria

Otsuka Reports Two-Year Kidney Function Benefit With Sibeprenlimab in Phase 3 IgA Nephropathy Trial

Sibeprenlimab-szsi (VOYXACT) slowed estimated glomerular filtration rate decline versus placebo over 24 months in adult patients with primary IgA nephropathy, according to Phase 3 VISIONARY results announced by Otsuka. Otsuka…

Continue Reading Otsuka Reports Two-Year Kidney Function Benefit With Sibeprenlimab in Phase 3 IgA Nephropathy Trial

Silence Therapeutics Advances Divesiran After Positive Phase 2 Results in Polycythemia Vera

As reported on Fierce Biotech, Silence Therapeutics reported positive phase 2 findings for divesiran, an investigational small interfering RNA (siRNA) treatment for polycythemia vera (PV), a rare blood cancer marked…

Continue Reading Silence Therapeutics Advances Divesiran After Positive Phase 2 Results in Polycythemia Vera